Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News TG Therapeutics Inc. TGTX

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:TGTX)

Fundamentals Snapshot (NDAQ:TGTX)

Current News (NDAQ:TGTX)

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of TG Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 16, 2022 - (NASDAQ: TGTX)

PR Newswire 56 minutes ago

ROSEN, A LEADING LAW FIRM, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TGTX

Newsfile 15 hours ago

SHAREHOLDER ACTON NOTICE: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile 21 hours ago

TGTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 16, 2022 in the Class Action Filed on Behalf of TG Therapeutics, Inc. Shareholders

PR Newswire 1 day ago

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - TGTX

PR Newswire 1 day ago

TG Therapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 16, 2022 to Discuss Your Rights - TGTX

Newsfile 1 day ago

SHAREHOLDER ACTON REMINDER: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile 1 day ago

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind TG Therapeutics Investors of a Lead Plaintiff Deadline of September 16, 2022

PR Newswire 2 days ago

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages TG Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - TGTX

Newsfile 3 days ago

Opinion & Analysis (NDAQ:TGTX)

Let volatility power your micro-cap biotechs

The Life Sciences Report April 28, 2016

Bullboard Posts (NDAQ:TGTX)

Any hope of recovery?

The stock is heading sout with 'strong buy' recommendation.  Where is the disconnect?
yellowtab - November 3, 2017